3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow ERCP: new trials by email Literature Review of ERCP trials Research Report on ERCP
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylaxis Against Post-Endoscopic Retrograde Cholangio-Pancreatography Pancreatitis. Rectal Indometacin - Pancreatitis, ERCP | Phase 3 | Completed | Hospital General de Chihuahua - Dr. Salvador Zubirán Anchondo | 60 | 2024-03-04 | 2026-05-20 |
| PPI for Prevention of Post-sphincterotomy Bleeding Esomeprazole, Standard care - Bleeding, ERCP | Phase 3 | Completed | The University of Hong Kong | 185 | 2013-04-01 | 2016-07-18 |
| Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP) Drotaverine hydrochloride, Hyoscine-N-butylbromide - ERCP, Pancreatic Diseases | Phase 3 | Completed | Changhai Hospital | 650 | 2008-08-01 | 2010-09-08 |
Bile Duct Diseases (1) · Hemorrhage (1) · Pancreatic Diseases (1) · Pancreatitis (1)
Digestive System Diseases (2) · Biliary Tract Diseases (1) · Pancreatic Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Butylscopolammonium Bromide (1) · Cholangiopancreatography, Endoscopic Retrograde (1) · Esomeprazole (1) · Standard of Care (1) · drotaverin (1)
Changhai Hospital (1) · Hospital General de Chihuahua - Dr. Salvador Zubirán Anchondo (1) · The University of Hong Kong (1)
China (2) · Mexico (1)
Wai K Leung, MD (1) · Zhaoshen Li, MD (1)